Riverbridge Partners LLC cut its Bio-Techne stake by 13.3% in Q4 but retains 785,788 shares worth $46.21 million. Bio-Techne exceeded Q4 earnings expectations with an EPS of $0.46 and revenue of $295.88 million, earning a "Moderate Buy" consensus rating from analysts.

NodeGuardian

2026-04-15 18:18:23

Abstract generation in progress

Riverbridge Partners LLC reduced its stake in Bio-Techne (NASDAQ:TECH) by 13.3% in Q4, but still holds 785,788 shares valued at $46.21 million. Bio-Techne reported stronger-than-expected Q4 earnings with EPS of $0.46 and revenue of $295.88 million. Analysts have a “Moderate Buy” consensus rating for the company, with an average price target of $72.77.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes

Reward
2
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
GatePreIPOsLaunchesWithSpaceX
133.45K Popularity
#
CryptoMarketRecovery
87.87K Popularity
#
US-IranTalksVSTroopBuildup
758.26K Popularity
#
USStocksHitRecordHighs
1.19M Popularity
#
WCTCTradingChallengeShare8MUSDT
620.23K Popularity

Sitemap

Riverbridge Partners LLC Has $46.21 Million Stake in Bio-Techne Corp $TECH

Trending Topics

GatePreIPOsLaunchesWithSpaceX

CryptoMarketRecovery

US-IranTalksVSTroopBuildup

USStocksHitRecordHighs

WCTCTradingChallengeShare8MUSDT

Pin